Clinical Research on RSV Prevention in Children and Pregnant Women: Progress and Perspectives
- 1University of Electronic Science and Technology of China, China
- 2University of Electronic Science and Technology Hospital, China
Respiratory syncytial virus (RSV) is a significant causative agent of bronchitis and pneumonia in infants and children. The identification and structural analysis of the surface fusion glycoprotein of RSV represents a pivotal advancement in the development of RSV prevention. This review provides a comprehensive summary of RSV monoclonal antibody (mAb) and vaccine clinical trials registered on ClinicalTrials.gov, emphasizing on the classification, name, target, phase, clinical outcomes, and safety data of RSV vaccination in newborns, infants and children. We also discuss the characteristics of the types of RSV vaccines for maternal immunity and summarize the current clinical research progress of RSV vaccination in pregnant women and their protective efficacy in infants. This review will provide new ideas for the development of RSV prevention for children in the future.
Keywords: RSV Vaccines, Monoclonal antibody, Clinical Trial, Children, Pregnant Women
Received: 28 Oct 2023;
Accepted: 28 Dec 2023.
Copyright: © 2023 Gong, Luo, Li, Zhang, Yang, Du, Yang and Xing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mx. Shasha Xing, University of Electronic Science and Technology of China, Chengdu, 611731, Sichuan Province, China